Overview

Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

Status:
Recruiting
Trial end date:
2022-01-18
Target enrollment:
Participant gender:
Summary
This 2-Part Randomized Clinical Study will evaluate the safety, tolerability and pharmacokinetics of alternate MK-8189 titration regimens. Part 1 will assess multiple dose once-daily titration regimens of MK-8189 in young adult participants with schizophrenia. Part 2 will assess multiple once-daily doses of MK-8189 in elderly participants with schizophrenia and healthy elderly participants.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.